Saleeva D.V. Saleeva

Saleeva D.V. Saleeva

Auto-generated profile, based on publicly available information

Saleeva D.V. Saleeva


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AKAlina Kirichenko
Alina Kirichenko
DKDmitry Kireev
Dmitry Kireev
ALAlexey Lopatukhin
Alexey Lopatukhin
AMAnastasia Murzakova
Anastasia Murzakova
ILIlya Lapovok
Ilya Lapovok
VPVadim Pokrovsky
Vadim Pokrovsky
Background: Eastern Europe and Central Asia (EECA) is one of the regions where the HIV epidemic continues to grow at a concerning rate. Antiretroviral therapy (ART) coverage in EECA countries has significantly increased during the last decade, which can lead to an increase in the risk of emergence, transmission, and spread of HIV variants with drug resistance (DR) that cannot be controlled. Because HIV genotyping cannot be performed in these countries, data about HIV DR are limited or unavailable. Objectives: To monitor circulating HIV-1 genetic variants, assess the prevalence of HIV DR among patients starting antiretroviral therapy, and reveal potential transmission clusters among patients in six EECA countries: Armenia, Azerbaijan, Belarus, Russia, Tajikistan, and Uzbekistan. Materials and methods: We analyzed 1071 HIV-1 pol-gene fragment sequences (2253–3369 bp) from patients who were initiating or reinitiating first-line ART in six EECA counties, i.e., Armenia (n = 120), Azerbaijan (n = 96), Belarus (n = 158), Russia (n = 465), Tajikistan (n = 54), and Uzbekistan (n = 178), between 2017 and 2019. HIV Pretreatment DR (PDR) and drug resistance mutation (DRM) prevalence was estimated using the Stanford HIV Resistance Database. The PDR level was interpreted according to the WHO standard PDR survey protocols. HIV-1 subtypes were determined using the Stanford HIV Resistance Database and subsequently confirmed by phylogenetic analysis. Transmission clusters were determined using Cluster Picker. Results: Analyses of HIV subtypes showed that EECA, in general, has the same HIV genetic variants of sub-subtype A6, CRF63_02A1, and subtype B, with different frequencies and representation for each country. The prevalence of PDR to any drug class was 2.8% in Uzbekistan, 4.2% in Azerbaijan, 4.5% in Russia, 9.2% in Armenia, 13.9% in Belarus, and 16.7% in Tajikistan. PDR to protease inhibitors (PIs) was not detected in any country. PDR to nucleoside reverse-transcriptase inhibitors (NRTIs) was not detected among patients in Azerbaijan, and was relatively low in other countries, with the highest prevalence in Tajikistan (5.6%). The prevalence of PDR to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) was the lowest in Uzbekistan (2.8%) and reached 11.1% and 11.4% in Tajikistan and Belarus, respectively. Genetic transmission network analyses identified 226/1071 (21.1%) linked individuals, forming 93 transmission clusters mainly containing two or three sequences. We found that the time since HIV diagnosis in clustered patients was significantly shorter than that in unclustered patients (1.26 years vs 2.74 years). Additionally, the K103N/S mutation was mainly observed in clustered sequences (6.2% vs 2.8%). Conclusions: Our study demonstrated different PDR prevalence rates and DR dynamics in six EECA countries, with worrying levels of PDR in Tajikistan and Belarus, where prevalence exceeded the 10% threshold recommended by the WHO for immediate public health action. Because DR testing for clinical purposes is not common in EECA, it is currently extremely important to conduct surveillance of HIV DR in EECA due to the increased ART coverage in this region.

20 September 2021 in Èpidemiologiâ i Infekcionnye Bolezni. Aktual’nye Voprosy
Verified
Journal Article
Closed access
AKAlina Kirichenko
Alina Kirichenko
DKDmitry Kireev
Dmitry Kireev
SSShlykova A.V. Shlykova
Shlykova A.V. Shlykova
ALAlexey Lopatukhin
Alexey Lopatukhin
ILIlya Lapovok
Ilya Lapovok
PPPokrovsky V.V. Pokrovsky
Pokrovsky V.V. Pokrovsky

1 December 2024 in Biology Bulletin
Verified
Journal Article
Closed access
PDF file
DFD. V. Fomina
D. V. Fomina
SAS. A. Abdullaev
S. A. Abdullaev
NRN. F. Raeva
N. F. Raeva
GZG. D. Zasukhina
G. D. Zasukhina
Natural species are widely used as pharmaceutical agents for treatment of many human diseases. One of these is the seeds of Nigella sativa and its constituent thymoquinone (TQ). As a biologically active compound, TQ manifests a variety of therapeutic properties, including antioxidant, anti-inflammatory, antitumor and some others. Since TQ is an absorber of free and superoxide radicals, it is a promising natural radioprotector against immunosuppressive and oxidative effects of ionizing radiation. The review presents the data on TQ radioprotective properties and some of the mechanisms of its activity. In addition, TQ exhibits antitumor activity by inhibiting cell proliferation, migration, and invasion. It is known that TQ can induce apoptosis by regulating the expression of pro-apoptotic and anti-apoptotic genes in many types of cancer, but the mechanism of TQ action in oncological diseases has not been fully studied yet. We described in this review the mechanisms of action of TQ as a promising radioprotector and as a future candidate for antitumor therapy.

12 October 2021 in Russian Journal of Genetics
Verified
Journal Article
Closed access
PDF file
VMV. F. Mikhailov
V. F. Mikhailov
DSD. V. Saleeva
D. V. Saleeva
LRL. M. Rozhdestvensky
L. M. Rozhdestvensky
LSL. V. Shulenina
L. V. Shulenina
NRN. F. Raeva
N. F. Raeva
GZG. D. Zasukhina
G. D. Zasukhina
The activity of genes and noncoding RNAs was studied in 183 hybrid mice (CBA × C57Bl) F1 after a prolonged low-power irradiation (within 21 h at a dose 12.6 Gy with a dose rate 10 mGy/min). The analysis of the studied parameters was carried out in the bone marrow of mice in the eighth and tenth months after irradiation. After ten month, radiation-induced malignant lymphomas in the liver, abdominal cavity, and subcutaneously were found in 14 out of 94 animals. The studied molecular genetic parameters were divided into two groups: oncogenes and tumor suppressors, the activation of which was compared at eighth and tenth months after irradiation. It was detected that the activity of tumor suppressors (PTEN gene and lncp21 long noncoding RNA) in the groups of mice with tumors was lower in comparison with the group of mice without cancer, while the activity of oncogenes (NFkB(p65), IkBα, iNOS, TAL1, CTCF, NEAT1 lncRNAs, and miR-125b) increased. The studied parameters can be considered as potential biomarkers of radiation-induced cancer.

17 September 2021 in Problems of Virology
Verified
Journal Article
Open access
PDF file
DSD. V. Saleeva
D. V. Saleeva
GZG. D. Zasukhina
G. D. Zasukhina
This review presents the literature data of new approaches for the treatment of COVID-19 with low doses of radiation (LDR). In addition, data on the use of LDR for the treatment of various disorders, in particular pneumonia, a number of inflammatory processes of various etiology, as well as Alzheimer’s disease are discussed. The mechanisms of LDR action are briefly described, associated with the activation of the immune system and antiinflammatory response due to the effect on the processes of oxidative stress, which is reflected in an increase in the activity of cytokines (interleukin- (IL-) 6), changes in the expression of a number of genes (such as P53 and NF-κB (p65)) and long non-coding RNAs (ncRNAs) (the authors’ own data are presented). Based on the analysis of the material presented, it can be assumed that further clinical trials of the effect of MDR (5–10 cGy) on patients with COVID-19, who are at different stages of the disease, will reveal the optimal conditions for the development and use of an effective treatment regimen.

3 November 2023 in Èpidemiologiâ i Infekcionnye Bolezni. Aktual’nye Voprosy
Verified
Journal Article
Closed access
DKDmitry Kireev
Dmitry Kireev
AKAlina Kirichenko
Alina Kirichenko
OOOsadchaya O.A. Osadchaya
Osadchaya O.A. Osadchaya
SDSaleeva D.V. Saleeva D
Saleeva D.V. Saleeva D
ILIlya Lapovok
Ilya Lapovok
VAVasily G Akimkin
Vasily G Akimkin